金融网络的模型和优化

金融网络就是经济系统中资金循环,文献[1-8]研究了金融网络的模型。本文则在文献[1-8]金融网络模型的基础之上,建立了资产、负债、适度规模和价格的改进模型。这一改进模型考虑了所有经济部门的金融工具的风险、金融网络的经济资源约束、资产和负债的会计帐户约束等问题。模型的改进适用于应用。文章采用了进化规划算法,并依此进行仿真实验。     

A new stratified three-stage unrelated randomized response model for estimating a rare sensitive attribute based on the Poisson distribution

This article suggests an efficient method of estimating a rare sensitive attribute which is assumed following Poisson distribution by using three-stage unrelated randomized response model instead of the Land et al. model (2011 Land, M., S. Singh, and S. A. Sedory. 2011. Estimation of a rare sensitive attribute using poisson distribution. Statistics 46 (3):351–60. doi:10.1080/02331888.2010.524300.[Taylor &; Francis Online], [Web of Science ®] , [Google Scholar]) when the population consists of some different sized clusters and clusters selected by probability proportional to size(:pps) sampling. A rare sensitive parameter is estimated by using pps sampling and equal probability two-stage sampling when the parameter of a rare unrelated attribute is assumed to be known and unknown.

We extend this method to the case of stratified population by applying stratified pps sampling and stratified equal probability two-stage sampling. An empirical study is carried out to show the efficiency of the two proposed methods when the parameter of a rare unrelated attribute is assumed to be known and unknown.     

Selecting the normal population with the smallest variance: A restricted subset selection rule

Consider k( ? 2) normal populations whose means are all known or unknown and whose variances are unknown. Let σ²_[1] ? ??? ? σ_[k]² denote the ordered variances. Our goal is to select a non empty subset of the k populations whose size is at most m(1 ? m ? k ? 1) so that the population associated with the smallest variance (called the best population) is included in the selected subset with a guaranteed minimum probability P* whenever σ²_[2]/σ_[1]² ? δ* > 1, where P* and δ* are specified in advance of the experiment. Based on samples of size n from each of the populations, we propose and investigate a procedure called R_BCP. We also derive some asymptotic results for our procedure. Some comparisons with an earlier available procedure are presented in terms of the average subset sizes for selected slippage configurations based on simulations. The results are illustrated by an example.     

A Five-Decision Testing Procedure to Infer the Value of a Unidimensional Parameter

ABSTRACT

A statistical test can be seen as a procedure to produce a decision based on observed data, where some decisions consist of rejecting a hypothesis (yielding a significant result) and some do not, and where one controls the probability to make a wrong rejection at some prespecified significance level. Whereas traditional hypothesis testing involves only two possible decisions (to reject or not a null hypothesis), Kaiser’s directional two-sided test as well as the more recently introduced testing procedure of Jones and Tukey, each equivalent to running two one-sided tests, involve three possible decisions to infer the value of a unidimensional parameter. The latter procedure assumes that a point null hypothesis is impossible (e.g., that two treatments cannot have exactly the same effect), allowing a gain of statistical power. There are, however, situations where a point hypothesis is indeed plausible, for example, when considering hypotheses derived from Einstein’s theories. In this article, we introduce a five-decision rule testing procedure, equivalent to running a traditional two-sided test in addition to two one-sided tests, which combines the advantages of the testing procedures of Kaiser (no assumption on a point hypothesis being impossible) and Jones and Tukey (higher power), allowing for a nonnegligible (typically 20%) reduction of the sample size needed to reach a given statistical power to get a significant result, compared to the traditional approach.     

Utilizing Bayesian predictive power in clinical trial design

The Bayesian paradigm provides an ideal platform to update uncertainties and carry them over into the future in the presence of data. Bayesian predictive power (BPP) reflects our belief in the eventual success of a clinical trial to meet its goals. In this paper we derive mathematical expressions for the most common types of outcomes, to make the BPP accessible to practitioners, facilitate fast computations in adaptive trial design simulations that use interim futility monitoring, and propose an organized BPP-based phase II-to-phase III design framework.     

Rare and clustered population estimation using the adaptive cluster sampling with some robust measures

The use of robust measures helps to increase the precision of the estimators, especially for the estimation of extremely skewed distributions. In this article, a generalized ratio estimator is proposed by using some robust measures with single auxiliary variable under the adaptive cluster sampling (ACS) design. We have incorporated tri-mean (TM), mid-range (MR) and Hodges-Lehman (HL) of the auxiliary variable as robust measures together with some conventional measures. The expressions of bias and mean square error (MSE) of the proposed generalized ratio estimator are derived. Two types of numerical study have been conducted using artificial clustered population and real data application to examine the performance of the proposed estimator over the usual mean per unit estimator under simple random sampling (SRS). Related results of the simulation study show that the proposed estimators provide better estimation results on both real and artificial population over the competing estimators.     

Non uniform exponential bounds on normal approximation by Stein’s method and monotone size bias couplings

It is known that the normal approximation is applicable for sums of non negative random variables, W, with the commonly employed couplings. In this work, we use the Stein’s method to obtain a general theorem of non uniform exponential bound on normal approximation base on monotone size bias couplings of W. Applications of the main result to give the bound on normal approximation for binomial random variable, the number of bulbs on at the terminal time in the lightbulb process, and the number of m runs are also provided.     

Business reform outcomes: Why so different?

Post-crisis policy making increasingly focuses on doing business reforms. We argue that the effects of those reforms will be different across countries. To understand the reasons for the reform outcome divergence, we advance a novel firm-size distribution (FSDs) argument. At the center of the argument is the fact that FSDs are different across countries and stable over time. Then, if a given doing business reform induces firms of different size to grow differently, this will produce a variety of reform outcomes across countries. To advance the argument, we set up a tractable general equilibrium (GE) model and study how firms of different size grow after a doing business reform. The model predicts that larger firms will grow faster than smaller firms after the reform. The model predictions are tested on the Enterprise Surveys (ES) data, merged with the Doing Business indicators. We confirm that firms of different size grow differently after a Doing Business reform. Thus, based on the notable differences of firm size distributions across countries, identical reforms to start, operate and close a business will produce a variety of reform outcomes across countries.     

Bayesian blinded sample size re-estimation

Information before unblinding regarding the success of confirmatory clinical trials is highly uncertain. Current techniques using point estimates of auxiliary parameters for estimating expected blinded sample size: (i) fail to describe the range of likely sample sizes obtained after the anticipated data are observed, and (ii) fail to adjust to the changing patient population. Sequential MCMC-based algorithms are implemented for purposes of sample size adjustments. The uncertainty arising from clinical trials is characterized by filtering later auxiliary parameters through their earlier counterparts and employing posterior distributions to estimate sample size and power. The use of approximate expected power estimates to determine the required additional sample size are closely related to techniques employing Simple Adjustments or the EM algorithm. By contrast with these, our proposed methodology provides intervals for the expected sample size using the posterior distribution of auxiliary parameters. Future decisions about additional subjects are better informed due to our ability to account for subject response heterogeneity over time. We apply the proposed methodologies to a depression trial. Our proposed blinded procedures should be considered for most studies due to ease of implementation.     

Sample size re‐estimation incorporating prior information on a nuisance parameter

Prior information is often incorporated informally when planning a clinical trial. Here, we present an approach on how to incorporate prior information, such as data from historical clinical trials, into the nuisance parameter–based sample size re‐estimation in a design with an internal pilot study. We focus on trials with continuous endpoints in which the outcome variance is the nuisance parameter. For planning and analyzing the trial, frequentist methods are considered. Moreover, the external information on the variance is summarized by the Bayesian meta‐analytic‐predictive approach. To incorporate external information into the sample size re‐estimation, we propose to update the meta‐analytic‐predictive prior based on the results of the internal pilot study and to re‐estimate the sample size using an estimator from the posterior. By means of a simulation study, we compare the operating characteristics such as power and sample size distribution of the proposed procedure with the traditional sample size re‐estimation approach that uses the pooled variance estimator. The simulation study shows that, if no prior‐data conflict is present, incorporating external information into the sample size re‐estimation improves the operating characteristics compared to the traditional approach. In the case of a prior‐data conflict, that is, when the variance of the ongoing clinical trial is unequal to the prior location, the performance of the traditional sample size re‐estimation procedure is in general superior, even when the prior information is robustified. When considering to include prior information in sample size re‐estimation, the potential gains should be balanced against the risks.